SCHEMBL4884791

SCHEMBL4884791

Cc1ccc(C)n1-c1cccnc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.53
CYP2E1 P05181 2/20 0.53
CYP3A4 P08684 2/20 0.53
ALOX12 P18054 1/20 0.49
KMT2A Q03164 2/20 0.44
GSR P00390 1/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
HPGD P15428 2/20 0.43
BLM P54132 1/20 0.43
PKM P14618 1/20 0.43
ELANE P08246 1/20 0.43
MDM2 Q00987 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28802526 0.82 ALOX12 (0.43) CYP2A6CYP2E1CYP3A4ALOX12KMT2A
SCHEMBL29728425 0.82 ALOX12 (0.43) CYP2A6CYP2E1CYP3A4ALOX12KMT2A
SCHEMBL30230906 0.81 CYP2A6 (0.56) CYP2A6CYP2E1CYP3A4ALOX12HTT
SCHEMBL30174245 0.78 MYC (0.49) ALOX12KMT2AGSRKDM4EALDH1A1
SCHEMBL25528988 0.78 MYC (0.49) ALOX12KMT2AGSRKDM4EALDH1A1
SCHEMBL30174246 0.77 MKNK1 (0.47) ALOX12KMT2AGSRKDM4EALDH1A1
SCHEMBL3607993 0.75 CYP2A6 (0.55) CYP2A6CYP2E1CYP3A4ALOX12HTT
SCHEMBL12349882 0.75 CYP2A6 (0.59) CYP2A6CYP2E1CYP3A4ALOX12HTT
SCHEMBL31456749 0.75 KMT2A (0.49) CYP2A6CYP2E1CYP3A4ALOX12KMT2A
SCHEMBL2724859 0.75 ALDH1A1 (0.48) CYP2A6CYP2E1CYP3A4ALOX12KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019152731-A1 ANDROGEN RECEPTOR ANTAGONISTS ALPINE ANDROSCIENCES, INC. (US) 2019-08-08 WO disclosed
US-9567301-B2 Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-02-14 US disclosed
US-9540320-B2 2017-01-10 US disclosed
US-20150291521-A1 PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. 2015-10-15 US disclosed
US-20080281105-A1 Novel Quinolinium Salts and Derivatives IMMUSOL INCORPORATED (US) 2008-11-13 US disclosed
EP-1841428-A1 NOVEL QUINOLINIUM SALTS AND DERIVATIVES Immusol Incorporated (US) 2007-10-10 EP disclosed
WO-2006078754-A1 NOVEL QUINOLINIUM SALTS AND DERIVATIVES IMMUSOL INCORPORATED (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080281105-A1 Novel Quinolinium Salts and Derivatives NQO2, MCL1, KRAS CYP2A6 4623/4885CYP2E1 4429/4885CYP3A4 3847/4885
US-20150291521-A1 PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS MYC, MYCBP, YAP1 CYP2A6 1996/4885CYP2E1 1109/4885CYP3A4 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.